Kymera Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Kymera Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-10.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 52% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 16%
Sales fell 16% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-16% / +189%In 3 years sales changed by -16% while total assets changed by +189%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-16.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 51% of Healthcare companies in United States.
Cash Cushion Ratio
+8%Cash, after subtracting all debt, equals 8% of its market value (net cash).
Lower than 52% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Kymera Therapeutics, Inc. made a loss over the last year. Kymera Therapeutics, Inc. owes $0.08 for every $1 it owns. Kymera Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossKymera Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
6.04The share price is 6.04 times Kymera Therapeutics, Inc.'s book value per share, higher than 77% of Healthcare companies in United States.
Market cap
$9.1 BThe total market value of all of Kymera Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 89% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.5 BWhat Kymera Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$18.35Net worth divided by the number of shares. The share price of $110.85 is 6.0 times this, which is the P/B above.
Return on equity (ROE)
-24.1%Kymera Therapeutics, Inc. lost 24.1% of its shareholders' money over the last year, higher than 64% of Healthcare companies in United States.
Owes vs Owns
0.08×Kymera Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Dividend yield
NoneKymera Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-17%Revenue fell 17% in the year to Dec 2025, and shrank 6% a year on average over 3 years.
Profit growth
LossKymera Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-794.0%Kymera Therapeutics, Inc. lost $794 for every $100 of revenue.
Interest cover
Not coveredKymera Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashKymera Therapeutics, Inc. held $766 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Kymera Therapeutics, Inc.: $9.1 B ÷ $1.5 B (30 Jun 2026) = 6.0.
What is Kymera Therapeutics, Inc.'s return on equity?
Kymera Therapeutics, Inc. lost 24.1% of its shareholders' money over the last year, higher than 64% of Healthcare companies in United States.
How much does Kymera Therapeutics, Inc. owe compared with what it owns?
Kymera Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Does Kymera Therapeutics, Inc. pay a dividend?
No. Kymera Therapeutics, Inc. does not currently pay a dividend.
Is Kymera Therapeutics, Inc.'s revenue growing?
Revenue fell 17% in the year to Dec 2025, and shrank 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.